What were the key takeaways from X4 Pharmaceuticals’s earnings call?

What were the key takeaways from X4 Pharmaceuticals's earnings call?

What is X4 Pharmaceuticals's gross profit margin?

What factors drove the changes in X4 Pharmaceuticals's revenue and profit?

What is the revenue and EPS growth rate for X4 Pharmaceuticals year over year?

What guidance did X4 Pharmaceuticals's management provide for the next earnings period?

What is X4 Pharmaceuticals's latest dividend and current dividend yield?

What is the market's earnings forecast for X4 Pharmaceuticals next quarter?

- **CN Market Breakthrough**: 4WARD trial enrollment on track for 2025, with heat map data supporting 60%+ infection rate reduction. US market potential: $1B-$2B.
- **WHIM Growth**: XOLREMDI sales hit $3.5M, 40% new patients. European approval pipeline opens $20M+ annual opportunity.
- **Financial Strength**: $89.9M cash, $30M+ annual savings from restructuring. Key partnerships expand global reach.
- **Clinical Momentum**: CN Phase 3 powered at >95% for ANC response, 90%+ for infection rate. WHIM patient adherence rates exceed expectations.


**【CEO Summary Section】**
- **Chronic Neutropenia (CN) Progress**: Launched pivotal Phase III 4WARD trial targeting 15,000 high unmet need CN patients in the US. Trial enrollment on track for Q3/Q4 2025, with data expected H2 2026. Heat map analysis from Phase 2/3 trials shows mavorixafor's potential to reduce infection rates by 60%.
- **WHIM Syndrome Commercialization**: XOLREMDI sales reached $3.5M since launch, with 40% of treated patients newly diagnosed. European MAA accepted for review, with potential approval Q1 2026. Partnerships with Norgine (Europe/Australia) and taiba rare (MENA) expand global reach.
- **Patent Milestone**: US patent for mavorixafor in CN granted until 2041, with similar applications pending globally. Estimated US market opportunity: $1B-$2B.

**【CFO Financial Commentary】**
- **Q1 2025 Financials**: $89.9M cash, $0.98M XOLREMDI revenue, $18.5M R&D, $15M SG&A. Net income driven by $28M Norgine license and $10.8M warrant gain. 
- **Cost Optimization**: Strategic restructuring to save $30M-$35M annually, including reverse stock split to meet NASDAQ listing rules.

**【Q&A Highlights】**
- **4WARD Trial Enrollment**: Patients with ANC <1000 cells/µL and ≥2 infections/year being prioritized. Physicians report high demand, with 95% of surveyed US CN specialists identifying >10 patients each.
- **Label Expansion Potential**: Phase 3 design supports broad CN indication, with Phase 2 data showing efficacy across idiopathic, autoimmune, and congenital subtypes.
- **Commercial Strategy**: Daily dosing compliance rates exceed expectations, with new patient education website (whimsyndrome.com) launched to build brand awareness.


X4 Pharmaceuticals (XFOR)-1 May 25-2025 Q1 Earnings call transcript

- **Breakthrough Year**: 2024 sales of $2.5M for XOLREMDI, with global partnerships unlocking $28.5M upfront and potential $226M milestones. 
- **CN Trial Momentum**: 90% site activation in 4WARD trial, targeting 15,000 U.S. CN patients. 
- **Cost Efficiency**: $30M-$35M annual savings from restructuring to focus on high-impact CN opportunity. 
- **Strong Adherence**: >90% patient compliance with XOLREMDI, supported by specialty pharmacy and peer-to-peer physician programs.

**【CEO Summary Section】**
- X4 Pharmaceuticals achieved a transformative 2024 with the U.S. launch of XOLREMDI (mavorixafor) for WHIM syndrome, generating $2.5 million in sales over 7.5 months. 
- Expanded global reach through partnerships: €28.5M upfront with Norgine for Europe and taiba rare for the Middle East, targeting regulatory approvals in 2026. 
- Advanced Phase III CN trial (4WARD) with 90% site activation, aiming for full enrollment by Q3/Q4 2025 and top-line data in H2 2026. 
- Restructured operations to reduce annual spending by $30M-$35M, focusing on CN as a larger market opportunity.

**【CFO Financial Commentary】**
- Ended 2024 with $103M cash, pro forma for Norgine payment, sufficient for operations into H1 2026. 
- XOLREMDI Q4 2024 revenue: $1.4M; full year: $2.6M. 
- R&D expenses: $21.7M (Q4) / $81.6M (FY); SG&A: $15.1M (Q4) / $61.5M (FY). 
- Net loss: $39.8M (Q4) / $37.5M (FY), excluding one-time $105M voucher sale.

**【Q&A Key Highlights】**
- **CN Trial Design**: FDA/EMA aligned on targeting moderate-severe neutropenia (ANC <1,000), reducing mild patient inclusion without impacting enrollment timelines. 
- **Patient Adherence**: >90% adherence to XOLREMDI, driven by specialty pharmacy partnerships and patient support programs. 
- **Global Expansion**: EMA MAA for WHIM expected to approve in Q1 2026; taiba rare to initiate named-patient programs in Saudi Arabia/Kuwait. 
- **Sales Growth**: 2025 focus on physician education and patient engagement, with U.S. WHIM patient base estimated at 1,000 and CN refractory population at 15,000.

X4 Pharmaceuticals (XFOR)-25 Mar 25-2024 Q4 Earnings call transcript

X4 Pharmaceuticals (XFOR)-13 Nov 24-2024 Q3 Earnings call transcript

X4 Pharmaceuticals (XFOR)-8 Aug 24-2024 Q2 Earnings call transcript

X4 Pharmaceuticals (XFOR)-7 May 24-2024 Q1 Earnings call transcript

X4 Pharmaceuticals (XFOR)-21 Mar 24-2023 Q4 Earnings call transcript

X4 Pharmaceuticals (XFOR)-9 Nov 23-2023 Q3 Earnings call transcript

X4 Pharmaceuticals (XFOR)-21 Mar 23-2022 Q4 Earnings call transcript

X4 Pharmaceuticals (XFOR)-3 Nov 22-2022 Q3 Earnings call transcript

X4 Pharmaceuticals (XFOR)-7 Aug 22-2022 Q2 Earnings call transcript

X4 Pharmaceuticals (XFOR)-12 May 22-2022 Q1 Earnings call transcript

X4 Pharmaceuticals (XFOR)-17 Mar 22-2021 Q4 Earnings call transcript

X4 Pharmaceuticals (XFOR)-6 Nov 21-2021 Q3 Earnings call transcript

X4 Pharmaceuticals (XFOR)-6 Aug 21-2021 Q2 Earnings call transcript

X4 Pharmaceuticals (XFOR)-9 May 21-2021 Q1 Earnings call transcript

X4 Pharmaceuticals (XFOR)-4 Mar 21-2020 Q4 Earnings call transcript

X4 Pharmaceuticals (XFOR)-7 Nov 20-2020 Q3 Earnings call transcript

X4 Pharmaceuticals (XFOR)-2 Aug 20-2020 Q2 Earnings call transcript

X4 Pharmaceuticals (XFOR)-9 May 20-2020 Q1 Earnings call transcript

X4 Pharmaceuticals (XFOR)-12 Mar 20-2019 Q4 Earnings call transcript

X4 Pharmaceuticals (XFOR)-10 Nov 19-2019 Q3 Earnings call transcript

Actual								-16.8	-22.8	-26.1	-27.3	-39	-22.2	-22.8	-37.2	-21.6	-18	-7.8	-8.7	-4.8	-9.9	-0.3	-3	-7.8	13.5	-5.4	-6	0.04	-3.47
Forecast								-23.7818	-21.5165	-22.6681	-27.0916	-25.15	-22.1625	-21.45	-20.2286	-18.0429	-19	-9	-8.1	-6.375	-4.8667	-4.4667	-4.3714	-4.6286	-0.2143	-5.1429	-5.28	-3.55	-3.938
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+29.36%	-5.97%	-15.14%	-0.77%	-55.07%	-0.17%	-6.29%	-83.90%	-19.71%	+5.26%	+13.33%	-7.41%	+24.71%	-103.42%	+93.28%	+31.37%	-68.52%	+6399.58%	-5.00%	-13.64%	+101.13%	+11.88%

Actual	--	--	--	--	--	--	--	3.00M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	563.00K	560.00K	1.43M	28.81M	1.97M
Forecast	--	--	--	--	--	--	--	0	0	0	0	0	0	0	0	128.57K	0	0	0	0	0	0	0	0	15.27M	1.69M	1.06M	11.58M	1.62M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-96.31%	-66.79%	+35.58%	+148.75%	+21.82%

XFOR

XFOR fundamentals

XFOR Q2 2025 Earnings

Earnings Call

You can ask Aime

XFOR

XFOR fundamentals

XFOR Q2 2025 Earnings

Earnings Call

XFOR Earnings Call Summary for Q2/2025 Apr 2, 2026

XFOR Earnings Call Summary for Q1/20258:30 AM on May 1, 2025

XFOR Earnings Call Summary for Q4/20248:30 AM on Mar 25, 2025

XFOR Earnings Call Summary for Q3/20248:00 AM on Nov 13, 2024

XFOR Earnings Call Summary for Q2/20248:30 AM on Aug 8, 2024

You can ask Aime